Morphic Therapeutic develops a new generation of oral integrin therapies using a structure-enabled integrin drug discovery platform. The company draws on integrin biology breakthroughs from the Springer lab and a partnership with computational chemistry firm Schrödinger to design clinical candidates. Morphic reports compelling preclinical data across multiple programs and has yielded several novel oral drug candidates targeting integrins. Its therapeutic focus areas include fibrosis, autoimmune diseases and immuno-oncology. Morphic recently completed an $80 million Series B financing to support clinical advancement. The company is based in Waltham, Mass. Morphic Therapeutic is a biotechnology company developing a new generation of oral integrin therapies. It was created in 2015 to translate discoveries from Timothy A. Springer’s laboratory into therapies for immunological, fibrotic, neoplastic and vascular diseases. Morphic has developed an exclusive platform that includes proprietary reagents, ultra‑high‑resolution integrin crystal structures, and a founding partnership with Schrödinger to support rapid, iterative small‑molecule design. The company’s programs target fibrosis, autoimmune diseases and immuno‑oncology and aim to overcome reasons behind prior failures of oral integrin candidates. Morphic plans to advance multiple programs into the clinic using its platform and partnerships. Leadership includes CEO Praveen Tipirneni and a development team with extensive industry drug‑development experience.

Total raised

$132M

Funding rounds

2

Latest round

Series B

Latest activity

Sep 2018